Literature DB >> 18196260

Phospholipases A2 in normal human conjunctiva and from patients with primary open-angle glaucoma and exfoliation glaucoma.

Minna Helin1, Seppo Rönkkö, Tuomo Puustjärvi, Markku Teräsvirta, Hannu Uusitalo.   

Abstract

BACKGROUND: Chronic situations like long-term use of topical medications induces conjunctival inflammation and is also a significant risk factor for failure of filtering surgery. We evaluated conjunctival expression of group IIA secretory PLA(2) (sPLA(2)-IIA), group V secretory PLA(2) (sPLA(2)-V), calcium-independent PLA(2) (iPLA(2)) and cytosolic PLA(2) (cPLA(2)).
METHODS: Samples were obtained from non-glaucomatous patients (control subjects), and patients with either primary open-angle glaucoma (POAG) or exfoliation glaucoma (ExG). All the glaucoma patients had been treated with antiglaucomatous medication, and underwent deep sclerectomy surgery. Antibodies against sPLA(2)-IIA, sPLA(2)-V, iPLA(2) and cPLA(2) were used for immunohistochemical staining of frozen tissue sections.
RESULTS: In the human conjunctiva of non-glaucomatous patients, immunostaining of sPLA(2)-IIA, sPLA(2)-V or cPLA(2) was low and positively stained cells were mainly localized in the surface of the epithelium. In contrast, iPLA(2) was found to predominate in human normal conjunctiva and it demonstrated strong labeling throughout the epithelium. The stromal staining of iPLA(2) was weak. Expression of sPLA(2)-IIA was significantly increased in stromal fibers of patients with POAG or ExG. No changes were found in levels of sPLA(2)-V, iPLA(2) or cPLA(2) between the patient groups and controls.
CONCLUSIONS: These findings demonstrate that sPLA(2)-IIA, sPLA(2)-V, iPLA(2) and cPLA(2) are expressed in the conjunctiva of non-glaucomatous patients. In the epithelium, sPLA(2)-IIA, sPLA(2)-V, and cPLA(2) may participate in protection against risks caused by mechanical wear and tear stress whereas iPLA(2) may regulate remodeling and maintenance of membrane phospholipids. sPLA(2)-IIA may also have the important role in the degradation of bacteria. In conjunctival stroma of POAG and ExG patients, sPLA(2)-IIA may play a role in the development of scar tissue after glaucoma filtration surgery.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18196260     DOI: 10.1007/s00417-007-0757-4

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  47 in total

1.  Secreted phospholipase A(2) induces vascular endothelial cell migration.

Authors:  M T Rizzo; E Nguyen; M Aldo-Benson; G Lambeau
Journal:  Blood       Date:  2000-12-01       Impact factor: 22.113

2.  Pathophysiological role of secretory type I and II phospholipase A2 in acute pancreatitis: an experimental study in rats.

Authors:  W Uhl; H J Schrag; N Schmitter; T J Nevalainen; J Aufenanger; A M Wheatley; M W Büchler
Journal:  Gut       Date:  1997-03       Impact factor: 23.059

3.  In vitro comparison of cytoprotective and antioxidative effects of latanoprost, travoprost, and bimatoprost on conjunctiva-derived epithelial cells.

Authors:  Jean-Marc Guenoun; Christophe Baudouin; Patrice Rat; Aude Pauly; Jean-Michel Warnet; Françoise Brignole-Baudouin
Journal:  Invest Ophthalmol Vis Sci       Date:  2005-12       Impact factor: 4.799

Review 4.  Management of glaucoma: focus on pharmacological therapy.

Authors:  Robert E Marquis; Jess T Whitson
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

Review 5.  Phospholipase A(2) in vascular disease.

Authors:  E Hurt-Camejo; G Camejo; H Peilot; K Oörni; P Kovanen
Journal:  Circ Res       Date:  2001-08-17       Impact factor: 17.367

6.  Antifibrotic activity of an inhibitor of group IIA secretory phospholipase A2 in young spontaneously hypertensive rats.

Authors:  Scott Levick; David Loch; Barbara Rolfe; Robert C Reid; David P Fairlie; Stephen M Taylor; Lindsay Brown
Journal:  J Immunol       Date:  2006-06-01       Impact factor: 5.422

7.  Roles of various phospholipases A2 in providing lysophospholipid acceptors for fatty acid phospholipid incorporation and remodelling.

Authors:  Jesús Balsinde
Journal:  Biochem J       Date:  2002-06-15       Impact factor: 3.857

8.  Structure and properties of a human non-pancreatic phospholipase A2.

Authors:  R M Kramer; C Hession; B Johansen; G Hayes; P McGray; E P Chow; R Tizard; R B Pepinsky
Journal:  J Biol Chem       Date:  1989-04-05       Impact factor: 5.157

9.  Foreshortening of the inferior conjunctival fornix associated with chronic glaucoma medications.

Authors:  I R Schwab; J V Linberg; V M Gioia; W H Benson; G M Chao
Journal:  Ophthalmology       Date:  1992-02       Impact factor: 12.079

Review 10.  Understanding and controlling the scarring response: the contribution of histology and microscopy.

Authors:  J T Daniels; N L Occleston; J G Crowston; M F Cordeiro; R A Alexander; M Wilkins; R Porter; R Brown; P T Khaw
Journal:  Microsc Res Tech       Date:  1998-09-01       Impact factor: 2.769

View more
  2 in total

1.  Present and New Treatment Strategies in the Management of Glaucoma.

Authors:  Kolko M
Journal:  Open Ophthalmol J       Date:  2015-05-15

2.  Gabapentin Attenuates Ocular Inflammation: In vitro and In vivo Studies.

Authors:  Carmelina D Anfuso; Melania Olivieri; Annamaria Fidilio; Gabriella Lupo; Dario Rusciano; Salvatore Pezzino; Caterina Gagliano; Filippo Drago; Claudio Bucolo
Journal:  Front Pharmacol       Date:  2017-04-04       Impact factor: 5.810

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.